Comparing Drug Safety of Hepatitis C Therapies Using Post-Market Data

BMC Medical Informatics and Decision Making - United Kingdom
doi 10.1186/s12911-019-0860-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

New Hepatitis C Therapies

Seminars in Liver Disease
Hepatology
2014English

Safety of Interferon-Free Therapies for Chronic Hepatitis C: A Network Meta-Analysis

Journal of Clinical Pharmacy and Therapeutics
Pharmacology
2016English

Towards Early Detection of Adverse Drug Reactions: Combining Pre-Clinical Drug Structures and Post-Market Safety Reports

BMC Medical Informatics and Decision Making
Health PolicyHealth Informatics
2019English

Good Progress With Novel Therapies for Hepatitis C

Future Virology
Virology
2008English

Post-Market Drug Surveillance Projects Developing Slowly

CMAJ
Medicine
2009English

Large-Scale Mining Disease Comorbidity Relationships From Post-Market Drug Adverse Events Surveillance Data

BMC Bioinformatics
BiochemistryApplied MathematicsComputer Science ApplicationsStructural BiologyMolecular Biology
2018English

C-C5-01: Drug Safety Data Mining With a Tree-Based Scan Statistic

Clinical Medicine and Research
MedicineHome CareCommunity
2011English

Analysis of Hepatitis C Virus Using Data Mining Algorithm -Apriori, Decision Tree

International Journal on Bioinformatics & Biosciences
2017English

Comparison of the Mechanisms of Drug Resistance Among HIV, Hepatitis B, and Hepatitis C

Viruses
VirologyInfectious Diseases
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy